Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma
U.S.-based ICER ICER has published its evidence report on therapies for multiple myeloma.
The report outlines the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA):
i) idecabtagene vicleucel (“ide-cel,” Abecma®, Bristol-Myers Squibb and bluebird bio), a chimeric antigen receptor (CAR) T-cell therapy that the FDA approved in March 2021.
ii) ciltacabtagene autoleucel (“cilta-cel,” Janssen and Legend Biotech), an investigational CAR T-cell therapy for which a rolling biologic license application (BLA) was submitted to the FDA in December 2020; and
iii) belantamab mafodotin-blmf (“belantamab,” Blenrep™, GlaxoSmithKline), which the FDA approved in August 2020.
While the report offered a relatively strong endorsement for CAR-T therapy in multiple myeloma, the agency concludes ide-cel’s recently announced price (list price of $419,500) would require at least a 37% discount to reach ICER’s recommended health-benefit price benchmark.